PROX1

Across TCGA pan-cancer cohorts, PROX1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PROX1 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher PROX1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PROX1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KICH, CESC, and OV are the cancer types where PROX1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.025	0.904	<.001	36	view →
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	32	view →
OV	OS	Median	IV	0.028	0.759	.002	12	view →
READ	DFS	Median	III,IV	0.182	0.745	.007	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	DFS	Median	All	0.945	0.607	.006	8	view →
COAD	OS	Median	All	0.249	0.702	.011	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PROX1–KICH (DFS)

Open the KICH breakdown →